Hoth Therapeutics (NASDAQ:HOTH) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Hoth Therapeutics (NASDAQ:HOTH) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

Separately, D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of Hoth Therapeutics in a research note on Thursday, June 12th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Hoth Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Hoth Therapeutics Price Performance

Shares of NASDAQ HOTH opened at $1.21 on Friday. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $3.80. The firm has a 50-day moving average of $0.98 and a 200 day moving average of $1.04. The stock has a market cap of $15.98 million, a P/E ratio of -1.06 and a beta of 0.55.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Monday, May 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.07. Research analysts expect that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Hoth Therapeutics stock. Geode Capital Management LLC grew its position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,946 shares of the company’s stock after buying an additional 13,038 shares during the quarter. Geode Capital Management LLC owned 1.39% of Hoth Therapeutics worth $72,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 7.08% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.